Based on recent research demonstrating the importance of the human microbiome in maintaining health, several biotech companies have been established to develop therapeutics for the human microbiome.
The human microbiome is critical to human health because it contains all beneficial microorganisms that do not cause diseases. It has been demonstrated that the microbes that live in the digestive tract provide numerous benefits to their host.
Biotech firms like Genofax have emerged in the current decade, intending to develop therapeutics that either directly target or use the beneficial properties of microbial communities such as the gut and skin microbiomes.
Meet Genofax
Genofax’s founder and CEO, Zahangir Alam, says that the company uses artificial intelligence and big data analytics to study the DNA and microbiome of humans, animals, and plants to develop cutting-edge nutritional advice and medical treatments for the future.
“Current medical and healthcare systems in our society are primarily concerned with treating symptoms rather than preventing and curing diseases. We at Genofax are working to change this status quo by creating personalised interventions for prevention, delay, and treatment of diseases that can benefit both humans and their canine companions,” he added.
Zahangir believes that modern medicine must incorporate AI now more than ever. “There is a wealth of unexplored information in databases that could provide crucial insights for making our ideas a reality.”
Identifying Genomic Signatures For A Healthy Life
Rapid scientific progress has never been more common than it is now. More data with greater depth and velocity than ever is constantly coming to light. An example is genome sequencing, which provides a magnified view of the molecular components of life. As a result of genome sequencing, new treatments for deadly diseases such as cancer, tuberculosis, and genetic disorders are being developed, and entire communities are being protected from potential harm.
AI has the potential to be a game-changing tool for personalised medicine because it can help doctors tailor care to each patient’s unique genomic profile. A recent study used artificial intelligence to examine the genomes of nearly 200,000 Europeans. The AI program discovered several genomic signatures linked to a longer lifespan. The results of the study show how artificial intelligence could help scientists find hidden patterns in genomic data. This could one day lead to the discovery of genomic signatures linked to a longer, healthier life.
“Genomic changes account for a lot of the differences between people and are part of what makes us unique. This variation is present in all species, but it is especially noticeable in humans. Our genes influence how we look, how tall we grow, what we eat, and how we deal with stress. Understanding the nuances of our own genetic makeup is now technologically feasible,” Zahangir explained.
He continued: “However, finding meaning in these inherited genomic changes is difficult. This challenge necessitates the use of cutting-edge artificial intelligence and machine learning tools. We can now develop highly accurate, personalised nutritional and health recommendations by combining knowledge of DNA alterations with AI and ML.”
Looking ahead
Analysts predict that the human microbiome market will grow at a 24% CAGR by 2027. Genofax intends to capitalise on this trend, becoming the next billion-dollar company while assisting animals, plants, and, eventually, humans in detecting diseases and living healthier lives.
“Genofax is unparalleled in its commitment to identifying and solving the blind spots in the healthcare industry’s current approach to early detection and treatment of diseases and cancer,” Zahangir points out. “We have been consistently impressed by the breakneck speed at which Genofax has developed and brought to market vital healthcare solutions.”
The company plans to launch its first product by early 2023, which will use gut microbiome sequencing to create precision probiotics to improve people’s overall health.
[ad unit=2]
